Litcius/Paper detail

Covid-19: UK approves monoclonal antibody sotrovimab for over 12s at high risk

Elisabeth Mahase

2021BMJ18 citationsDOI

Abstract

Covid-19: UK approves monoclonal antibody sotrovimab for over 12s at high risk Elisabeth MahaseThe UK's medicines regulator has approved a second monoclonal antibody, sotrovimab, for the treatment of people over 12 years with mild to moderate covid-19 who are at high risk of developing severe disease. 1 1

Topics & Concepts

Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Monoclonal antibodyVirologyMedicineAntibodyComputer scienceImmunologyInternal medicineOutbreakInfectious disease (medical specialty)DiseaseHealthcare Systems and Challenges
Covid-19: UK approves monoclonal antibody sotrovimab for over 12s at high risk | Litcius